Cancer cell dormancy in novel mouse models for reversible pancreatic cancer: A lingering challenge in the development of targeted therapies

Cancer Research

Volumn 74, Issue 8, 2014, Pages 2138-2143

  Lin, Wan Chi ^a   Rajbhandari, Nirakar ^a,b   Wagner, Kay Uwe ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; IMATINIB;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL DORMANCY; CANCER RECURRENCE; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; GENE MUTATION; GENETIC MODEL; HUMAN; METASTASIS; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MOUSE MODEL; NONHUMAN; ONCOGENE C MYC; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR ENGRAFTMENT; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; MICE; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS;

EID: 84899507722     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3437     Document Type: Article

References (37)

1. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-46.
2. Ranganathan AC, Adam AP, Aguirre-Ghiso JA. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 2006;5:1799-807.
3. Paez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, et al. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res 2012;18:645-53.
4. Pusztai L, Asmar L, Smith TL, Hortobagyi GN. Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer. Breast Cancer Res Treat 1999;55:1-8.
5. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 2006;13:1033-67.
6. Demicheli R. Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin Cancer Biol 2001;11:297-306.
7. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.
8. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 2003;82:199-206.
9. Marlow R, Honeth G,Lombardi S, Cariati M, Hessey SM, Pipili A, et al.A novel model of dormancy for bone metastatic breast cancer cells. Cancer Res 2013;73:6886-99.
10. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 2013;15:807-17.
11. Barkan D, El Touny LH, Michalowski AM, Smith JA, Chu I, Davis AS, et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res 2010;70:5706-16.
12. Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008;13:507-18.
13. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004;104:2204-5.
14. Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012;119:1501-10.
15. Ewald D, Li M, Efrat S, Auer G, Wall RJ, Furth PA, et al. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science 1996;273:1384-6.
16. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999;4:199-207.
17. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001;15:3249-62.
18. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002;2:451-61.
19. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al.MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-7.
20. Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004;6:577-86.
21. Podsypanina K, Politi K, Beverly LJ, Varmus HE. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci U S A 2008;105:5242-7.
22. Jonkers J, Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell 2004;6:535-8.
23. Shachaf CM, Felsher DW. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res 2005;65:4471-4.
24. Sultana A, Tudur SC, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-Analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 2008;99:6-13.
25. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909.
26. Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, Galban CJ, et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012;22:639-53.
27. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism. Cell 2012;149:656-70.
28. Collins MA, Brisset JC, Zhang Y, Bednar F, Pierre J, Heist KA, et al. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One 2012;7:e49707.
29. Lin WC, Rajbhandari N, Liu C, Sakamoto K, Zhang Q, Triplett AA, et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res 2013;73:1821-30.
30. Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, O'Hare T, et al. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia 2012;26:1140-3.
31. Borovski T, De Sousa E Melo, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res 2011;71:634-9.
32. Lonardo E, Frias-Aldeguer J, Hermann PC, Heeschen C. Pancreatic stellate cells form a niche for cancer stem cells and promote their selfrenewal and invasiveness. Cell Cycle 2012;11:1282-90.
33. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80.
34. Vermeulen L, De Sousa E Melo, van der Heijden M, Cameron K, de Jong JH, Borovski T, et al.Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010;12: 468-76.
35. Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, et al. Defining the epithelial stem cell niche in skin. Science 2004;303: 359-63.
36. Kalisky T, Quake SR. Single-cell genomics. Nat Methods 2011;8: 311-4.
37. Dalerba P, Kalisky T, Sahoo D, Rajendran PS, Rothenberg ME, Leyrat AA, et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol 2011;29:1120-7.